U.S. stocks rise on Fed cut bets; earnings continue to flow
On Monday, Ascendiant Capital adjusted its price target for Cyclo Therapeutics (NASDAQ:CYTH), a clinical-stage biotechnology company, reducing it to $0.95 from the previous target of $2.60. Despite this reduction, the firm maintained a Buy rating on the company's stock.
The revision follows Cyclo Therapeutics' announcement on May 30 that it had completed enrollment for its 108-patient pivotal phase 3 trial of Trappsol Cyclo, a leading drug candidate for the treatment of Niemann-Pick Disease Type C (NPC). The completion of enrollment is a significant step for Cyclo Therapeutics, as it keeps the company on schedule for an interim data analysis in the first half of 2025.
If the interim data from the trial prove to be significant, Cyclo Therapeutics anticipates filing a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application with the European Medicines Agency (EMA) in the second half of 2025. This would position the company for potential FDA approval of the drug by the first quarter of the fiscal year 2026.
The market opportunity for NPC treatments in the United States is estimated to be around $300 million annually. Cyclo Therapeutics is expected to market the drug independently due to its existing interactions with the NPC community through clinical research.
In light of recent developments, Ascendiant Capital has also revised its earnings per share (EPS) estimates for Cyclo Therapeutics. The firm now projects a fiscal year 2024 EPS of $(0.77), down from the previous estimate of $(0.74), and a fiscal year 2025 EPS of $(0.83), down from $(0.80), attributing the adjustments to lower expenses.
These figures contrast with the consensus estimates of $(0.63) and $(0.65) for fiscal years 2024 and 2025, respectively. The revenue estimates remain unchanged at $1.2 million for fiscal year 2024 and $1.3 million for fiscal year 2025.
In other recent news, Cyclo Therapeutics has seen significant developments. The company's stock was downgraded from Buy to Neutral by H.C. Wainwright, following the announcement of an acquisition by Rafael Holdings.
The acquisition will be for $0.95 per share, marking a 25% discount to Cyclo Therapeutics' closing share price before the announcement. The merger aims to advance the development of Trappsol® Cyclo™, a treatment for the rare genetic disorder Niemann-Pick Disease Type C1.
Cyclo Therapeutics has also secured a $2 million convertible promissory note deal with Rafael Holdings. The note, bearing a 5% annual interest rate, is set to mature in 2024. The proceeds from this note are planned to be allocated towards working capital and general corporate purposes.
In addition, the company has made significant strides in its Alzheimer's disease treatment program, securing approval from the European Patent Office for its Alzheimer's disease treatment method. The patent, numbered 3873604B, is set to take effect in 2024.
These are recent developments in Cyclo Therapeutics' ongoing efforts to secure funding, gain analyst recognition, and expand its product range.
InvestingPro Insights
In the context of Ascendiant Capital's price target adjustment for Cyclo Therapeutics, current data from InvestingPro provides additional insights into the company's financial health and market performance. Notably, Cyclo Therapeutics has a market capitalization of $22.38 million, which reflects the company's valuation in the biotechnology industry. Despite the challenges, the company boasts an impressive gross profit margin of 91.56% as of the last twelve months leading up to Q2 2024, highlighting its ability to maintain profitability on the cost of goods sold.
InvestingPro Tips indicate that Cyclo Therapeutics' net income is expected to grow this year, which could signal a positive turn for the company despite recent stock price volatility. The stock has taken significant hits, trading near its 52-week low and down 36.84% over the last week. This could suggest a potential buying opportunity for investors, as the Relative Strength Index (RSI) suggests the stock is in oversold territory. It's important to note that analysts anticipate a sales decline in the current year, which should be considered when evaluating the company's future revenue streams.
For investors seeking a deeper analysis, InvestingPro offers additional tips on Cyclo Therapeutics, providing a broader perspective on the company's financial outlook and market behavior. To explore these further, investors can access more tips on https://www.investing.com/pro/CYTH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.